JP2023532917A5 - - Google Patents
Info
- Publication number
- JP2023532917A5 JP2023532917A5 JP2022581341A JP2022581341A JP2023532917A5 JP 2023532917 A5 JP2023532917 A5 JP 2023532917A5 JP 2022581341 A JP2022581341 A JP 2022581341A JP 2022581341 A JP2022581341 A JP 2022581341A JP 2023532917 A5 JP2023532917 A5 JP 2023532917A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- recombinant
- gene
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063047978P | 2020-07-03 | 2020-07-03 | |
| US63/047,978 | 2020-07-03 | ||
| US202063114131P | 2020-11-16 | 2020-11-16 | |
| US63/114,131 | 2020-11-16 | ||
| PCT/US2021/039953 WO2022006309A1 (en) | 2020-07-03 | 2021-06-30 | Methods and compositions for editing the b2m locus in b cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023532917A JP2023532917A (ja) | 2023-08-01 |
| JP2023532917A5 true JP2023532917A5 (cg-RX-API-DMAC10.html) | 2024-07-04 |
Family
ID=79315579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022581341A Pending JP2023532917A (ja) | 2020-07-03 | 2021-06-30 | B細胞のb2m遺伝子座を編集するための方法および組成物 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4175651A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2023532917A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20230035048A (cg-RX-API-DMAC10.html) |
| CN (1) | CN116033910A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021300358A1 (cg-RX-API-DMAC10.html) |
| BR (1) | BR112022026534A2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3186620A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL299491A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2022015788A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022006309A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023187779A1 (en) * | 2022-03-28 | 2023-10-05 | Ramot At Tel-Aviv University Ltd. | Site-specific in vivo t cell engineering, systems, compositions and methods thereof |
| EP4565716A4 (en) * | 2022-08-01 | 2026-07-15 | Idexx Lab Inc | FRACTIONAL ABUNDANCE DOSES OF HUMAN MOUSE |
| KR20250175332A (ko) * | 2023-04-17 | 2025-12-16 | 비이 바이오파마, 인크. | 혈우병 치료를 위한 조작된 세포 제제 |
| CN120866304A (zh) * | 2024-04-23 | 2025-10-31 | 南京奇迹生物科技有限公司 | 对b2m基因座的基因编辑方法 |
| KR102955030B1 (ko) * | 2025-11-04 | 2026-04-23 | 대한민국 | 신규한 가이드 rna 및 이의 용도 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016073955A2 (en) * | 2014-11-06 | 2016-05-12 | President And Fellows Of Harvard College | Cells lacking b2m surface expression and methods for allogeneic administration of such cells |
| AU2016374253B2 (en) * | 2015-12-18 | 2021-10-21 | Sangamo Therapeutics, Inc. | Targeted disruption of the MHC cell receptor |
| AU2018292181B2 (en) * | 2017-06-30 | 2025-04-10 | Cellectis | Cellular immunotherapy for repetitive administration |
| SG11202004529XA (en) * | 2017-11-16 | 2020-06-29 | Mogam Inst Biomedical Res | Transformed human cell and use thereof |
| US12378572B2 (en) * | 2018-09-07 | 2025-08-05 | Crispr Therapeutics Ag | Universal donor cells |
| AU2019341365A1 (en) * | 2018-09-21 | 2021-05-27 | Crage Medical Co., Limited | Method for gene editing of cell on the basis of CRISPR/Cas system |
| UY38427A (es) * | 2018-10-26 | 2020-05-29 | Novartis Ag | Métodos y composiciones para terapia con células oculares |
-
2021
- 2021-06-30 WO PCT/US2021/039953 patent/WO2022006309A1/en not_active Ceased
- 2021-06-30 EP EP21832140.4A patent/EP4175651A4/en active Pending
- 2021-06-30 KR KR1020237001885A patent/KR20230035048A/ko active Pending
- 2021-06-30 BR BR112022026534A patent/BR112022026534A2/pt unknown
- 2021-06-30 CN CN202180047549.4A patent/CN116033910A/zh active Pending
- 2021-06-30 IL IL299491A patent/IL299491A/en unknown
- 2021-06-30 CA CA3186620A patent/CA3186620A1/en active Pending
- 2021-06-30 JP JP2022581341A patent/JP2023532917A/ja active Pending
- 2021-06-30 AU AU2021300358A patent/AU2021300358A1/en active Pending
- 2021-06-30 MX MX2022015788A patent/MX2022015788A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7194230B2 (ja) | クローディン-18.2-特異的免疫受容体およびt細胞エピトープ | |
| JP6538622B2 (ja) | ホモ二量体タンパク質コンストラクト | |
| EP3511413B1 (en) | Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule | |
| KR20230172630A (ko) | 종양 네오 항원성 펩타이드 | |
| JP2020509780A5 (cg-RX-API-DMAC10.html) | ||
| JP2021168662A (ja) | 免疫グロブリンの産生増強 | |
| US20150218260A1 (en) | Interleukin-2 fusion proteins and uses thereof | |
| RU2019119272A (ru) | Вирусная доставка неоантигенов | |
| JP2024519515A5 (cg-RX-API-DMAC10.html) | ||
| KR20230172047A (ko) | 종양 신생항원 펩타이드 및 이의 용도 | |
| RS61387B2 (sr) | Gen optimizovanog faktora viii | |
| KR20240006721A (ko) | 막 형질 전환 네오 안티젠 펩타이드 | |
| Kroczek et al. | Structure-function relationship of XCL1 used for in vivo targeting of antigen into XCR1+ dendritic cells | |
| JP2023532917A (ja) | B細胞のb2m遺伝子座を編集するための方法および組成物 | |
| JP2023526587A (ja) | 改変型上皮成長因子受容体及び細胞追跡におけるその使用 | |
| TW201124535A (en) | SORF constructs and multiple gene expression | |
| Boulanger et al. | Absence of tapasin alters immunodominance against a lymphocytic choriomeningitis virus polytope | |
| WO2020219504A1 (en) | Modulating survival of therapeutic cells and methods, cells and nucleic acids related thereto | |
| Simpson et al. | FcγRIIB (CD32B) antibodies enhance immune responses through activating FcγRs | |
| CN1511163A (zh) | 抗体制备与筛选方法 | |
| KR20250021382A (ko) | 바이러스 펩티드 및 이의 용도 | |
| US12162925B2 (en) | DNA-encoded monoclonal antibodies targeting the Ebolavirus glycoprotein | |
| CN1194089C (zh) | 大胡蜂镇静肽前体基因及其编码的多肽和制备方法 | |
| KR20060135280A (ko) | 선천성 면역에 관여하는 트렘-2의 클로닝 | |
| EP4501954A1 (en) | A nucleic acid encoding a cd8 alpha beta co-receptor, cells and pharmaceutical compositions comprising the same |